# CRISPR Therapeutics to Participate in Upcoming Investor Conferences
Canonical URL: https://biopharmsignal.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences
Ticker: CRSP
Company: CRISPR Therapeutics
Source: CRISPR Therapeutics
Published: 2026-06-25 13:46 EST
Original Source URL: https://ir.crisprtx.com
## Summary

ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. Jefferies Global Healthcare Conference Date: Wednesday, June 3,

## Article Body
ZUG, Switzerland and BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that members of its senior management team are scheduled to participate in the following investor conferences in June. Jefferies Global Healthcare Conference Date: Wednesday, June 3,
## Recent Company News
- 2026-06-25 13:46 EST — [CRISPR Therapeutics to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/CRSP/crispr-therapeutics-to-participate-in-upcoming-investor-conferences) — Source: CRISPR Therapeutics
- 2026-06-25 13:46 EST — [CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2025 Financial Results](https://biopharmsignal.com/news/CRSP/crispr-therapeutics-provides-business-update-and-reports-third-quarter-2025-financial-results) — Source: CRISPR Therapeutics
- 2026-06-25 13:46 EST — [CRISPR Therapeutics Provides Broad Update on Zugocaptagene Geleucel (Zugo-cel; formerly CTX112™) in Autoimmune Diseases and Hematologic Malignancies](https://biopharmsignal.com/news/CRSP/crispr-therapeutics-provides-broad-update-on-zugocaptagene-geleucel-zugo-cel-formerly-ctx112tm-in-autoimmune-diseases-and-hematologic-malignancies) — Source: CRISPR Therapeutics
- 2026-06-25 13:46 EST — [CRISPR Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference](https://biopharmsignal.com/news/CRSP/crispr-therapeutics-to-present-at-the-44th-annual-j-p-morgan-healthcare-conference) — Source: CRISPR Therapeutics
- 2026-06-25 13:46 EST — [CRISPR Therapeutics Highlights Strategic Priorities and Anticipated 2026 Milestones](https://biopharmsignal.com/news/CRSP/crispr-therapeutics-highlights-strategic-priorities-and-anticipated-2026-milestones) — Source: CRISPR Therapeutics
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)
- 2026-07-20 13:00 EST — ENLV — [Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion](https://biopharmsignal.com/news/ENLV/enlivex-treasury-portfolio-update-nav-per-ordinary-share-66-16-total-treasury-ho-9d036ef9)